SEC Form 4 · accession 0001209191-15-026882

Horizon Pharma plc · HZNP

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Mar 12, 2015

Accepted (ET)

Mar 17, 2015 · 2:18 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001492426

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1,F2	Mar 12, 2015	X	690,369	$4.308	A	690,369	I	See Foot note
Common Stock^F3,F2	Mar 12, 2015	D	135,805	$4.038	D	554,564	I	See Foot note
Common Stock^F4,F2	Mar 12, 2015	S	197,277	$22.59	D	357,287	I	See Foot note
Common Stock^F5,F2	Mar 13, 2015	S	357,287	$22.35	D	0	I	See Foot note

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Warrant^F2	$4.308	Mar 12, 2015	X	690,369	D	Mar 2, 2012	Mar 2, 2017	Common Stock	690,369	690,369	I

F1Represents shares underlying warrants. Essex Woodlands Health Ventures Fund, VII, L.P. (the "Fund") exercised warrants for 690,369 shares. Shares received by the Fund are net of shares withheld, as described in footnote (3), due to net exercise of warrants.
F2The securities are held directly by the Fund. The Reporting Person is a manager of Essex Woodlands Health Ventures VII, L.L.C., which is the general partner of Essex Woodlands Health Ventures VII, L.P., the general partner of the Fund. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein.
F3Represents 135,805 shares withheld in connection with the net exercise of warrants. Such shares are held by the issuer in satisfaction of the warrant's exercise price and did not involve any sale of shares by the Fund.
F4Price Range of $22.41 to $22.90.
F5Price Range of $22.20 to $22.62.